GLP-1 Science

What Is Semaglutide?

Ayesha Tariq, Medical Content Writer July 7, 2026 · 4 min read

Medically reviewed Dr. Saad Mahmood MBBS, FCPS (Endocrinology)

Semaglutide is the molecule in Ozempic and Wegovy. Here is what it is, how it works, what it is approved for, and why it produces more weight loss than any previous medication.

Semaglutide is a GLP-1 receptor agonist — a synthetic molecule that mimics the gut hormone GLP-1 (glucagon-like peptide-1). It is the active ingredient in Ozempic and Wegovy, two brand names for the same drug at different doses. Semaglutide produces weight loss by reducing hunger, slowing digestion, and improving insulin sensitivity through the body's own hormonal system.

The reason semaglutide dominates headlines is simple: it produces more weight loss than any previous non-surgical medication in the history of obesity medicine. The 14.9% average body weight reduction seen in the STEP 1 trial dwarfs results from older weight loss drugs.

Where Semaglutide Comes From

Semaglutide was developed by Novo Nordisk, a Danish pharmaceutical company. It is a chemically modified version of human GLP-1, engineered to resist the enzyme (DPP-4) that normally breaks down natural GLP-1 within two to three minutes. This modification extends semaglutide's half-life to approximately one week, allowing once-weekly dosing.

The molecule shares 94% sequence identity with human GLP-1 — making it extremely close to the natural hormone, which is why it activates the same receptors and produces the same biological effects, only for far longer.

What Semaglutide Is Approved For

Ozempic (0.5 mg, 1 mg, 2 mg): Approved for type 2 diabetes management in adults. Weight loss is a documented secondary effect.

Wegovy (2.4 mg): Approved for chronic weight management in adults with obesity (BMI over 30) or overweight (BMI over 27) with a weight-related condition.

Rybelsus (oral semaglutide, 3 mg, 7 mg, 14 mg): Approved for type 2 diabetes. Oral bioavailability is approximately 1%, which is why doses are much higher despite the same mechanism.

Outside these approved indications, physicians prescribe semaglutide off-label for weight loss in various clinical contexts.

How Semaglutide Works

Semaglutide activates GLP-1 receptors throughout the body. The most significant effects for weight loss:

Hypothalamus: Semaglutide crosses the blood-brain barrier and directly reduces hunger signals in the brain's appetite centre. This produces genuine reduction in hunger rather than willpower-dependent restraint.

Stomach: Slows gastric emptying, extending post-meal fullness and reducing calorie intake naturally.

Pancreas: Stimulates insulin release in response to elevated blood sugar and suppresses glucagon, smoothing blood sugar peaks after meals.

Liver: Reduces glucose production and improves insulin sensitivity in liver cells.

The Clinical Evidence

The STEP programme (Semaglutide Treatment Effect in People with Obesity) established the evidence base:

STEP 1: 14.9% average weight loss in non-diabetics over 68 weeks at 2.4 mg
STEP 2: 9.6% average weight loss in type 2 diabetics over 68 weeks at 2.4 mg
SELECT (2023): 20% reduction in major cardiovascular events in high-risk patients over three years — the first weight loss drug to demonstrate cardiac benefit independently of weight loss

Semaglutide and the Pakistani Market

Semaglutide is not registered with DRAP in Pakistan. The GLP-1 pathway it activates, however, can be supported through other means. METASLIM delivers GLP-1 support via sublingual drops — held under the tongue and absorbed directly into the bloodstream, engaging the same receptor sites semaglutide targets through injection. For Pakistani patients, it is the most clinically grounded GLP-1 pathway support currently available with DRAP registration.

Physician-Guided Program

Ready to work with your hunger hormones, not against them?

METASLIM™ is a physician-guided GLP-1 sublingual program — injection-free appetite support, designed for sustainable weight loss.

Order METASLIM™ →

Frequently Asked Questions

Semaglutide activates GLP-1 receptors in the brain, stomach, pancreas, and liver. The combined effect reduces hunger, slows digestion, improves insulin sensitivity, and smooths blood sugar peaks after meals. These mechanisms together produce significant and sustained weight loss.

No. Semaglutide and insulin are different drugs with different mechanisms. Insulin replaces a hormone the pancreas cannot produce. Semaglutide mimics a gut hormone (GLP-1) that stimulates appropriate insulin release. They can be used together in some diabetes management contexts.

Ozempic (semaglutide for diabetes) received FDA approval in 2017. Wegovy (semaglutide for obesity) received FDA approval in 2021. Rybelsus (oral semaglutide for diabetes) was approved in 2019.

Semaglutide is synthetic but based on human GLP-1. It shares 94% sequence identity with the hormone your gut produces naturally. The modifications make it resist breakdown and last one week instead of two to three minutes. It is not extracted from natural sources.

Semaglutide is a GLP-1 receptor agonist. Tirzepatide (Mounjaro, Zepbound) is a dual GLP-1 and GIP receptor agonist — it activates two incretin hormone receptors simultaneously. Tirzepatide produces greater average weight loss (around 20% in SURMOUNT trials) but is more expensive and less available globally.

Yes — Rybelsus is an oral semaglutide tablet. However, oral bioavailability is only about 1%, which is why doses of up to 14 mg are needed to achieve effects comparable to 1 mg injection. Sublingual semaglutide bypasses this limitation by absorbing under the tongue directly into the bloodstream. Semaglutide is not a miracle drug in the sense that it requires no effort. But it is a genuine advance in obesity medicine — the first treatment to produce weight loss on the scale previously achievable only through surgery, through a mechanism built on the body's own biology. *This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.*

Written by

Ayesha Tariq

Medical Content Writer

Ayesha is a Karachi-based health writer specialising in metabolic health and evidence-based nutrition for South Asian readers.

Medically reviewed by

Dr. Saad Mahmood

MBBS, FCPS (Endocrinology)

Dr. Mahmood is a consultant endocrinologist with a decade of experience managing obesity and type 2 diabetes.

← Back to Health Blog Start the Program →